Cargando…

Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder

BACKGROUND: The transition from methamphetamine (MA) casual use (MCU) to compulsive use is enigmatic as some MA users can remain in casual use, but some cannot. There is a knowledge gap if gut microbiota (GM) play a role in differing MCU from MA use disorder (MUD). We aimed to investigate the clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Li, Yang, Bao-Zhu, Ma, Yue-Jiao, Wen, Li, Liu, Feng, Zhang, Xiao-Jie, Liu, Tie-Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996337/
https://www.ncbi.nlm.nih.gov/pubmed/36909722
http://dx.doi.org/10.3389/fcimb.2023.1103919
_version_ 1784903022831206400
author He, Li
Yang, Bao-Zhu
Ma, Yue-Jiao
Wen, Li
Liu, Feng
Zhang, Xiao-Jie
Liu, Tie-Qiao
author_facet He, Li
Yang, Bao-Zhu
Ma, Yue-Jiao
Wen, Li
Liu, Feng
Zhang, Xiao-Jie
Liu, Tie-Qiao
author_sort He, Li
collection PubMed
description BACKGROUND: The transition from methamphetamine (MA) casual use (MCU) to compulsive use is enigmatic as some MA users can remain in casual use, but some cannot. There is a knowledge gap if gut microbiota (GM) play a role in differing MCU from MA use disorder (MUD). We aimed to investigate the clinical features and GM differences between individuals with MCU and MUD. METHOD: We recruited two groups of MA users –MCU and MUD – and matched them according to age and body mass index (n=21 in each group). Participants were accessed using the Semi-Structured Assessment for Drug Dependence and Alcoholism, and their fecal samples were undergone 16S ribosomal DNA sequencing. We compared the hosts’ clinical features and GM diversity, composition, and structure (represented by enterotypes) between the two groups. We have identified differential microbes between the two groups and performed network analyses connecting GM and the clinical traits. RESULT: Compared with the casual users, individuals with MUD had higher incidences of MA-induced neuropsychiatric symptoms (e.g., paranoia, depression) and withdrawal symptoms (e.g., fatigue, drowsiness, and increased appetite), as well as stronger cravings for and intentions to use MA, and increased MA tolerance. The GM diversity showed no significant differences between the two groups, but four genera (Halomonas, Clostridium, Devosia, and Dorea) were enriched in the individuals with MUD (p<0.05). Three distinct enterotypes were identified in all MA users, and Ruminococcus-driven enterotype 2 was dominant in individuals with MUD compared to the MCU (61.90% vs. 28.60%, p=0.03). Network analysis shows that Devosia is the hub genus (hub index = 0.75), which is not only related to the counts of the MUD diagnostic criteria (ρ=0.40; p=0.01) but also to the clinical features of MA users such as reduced social activities (ρ=0.54; p<0.01). Devosia is also associated with the increased intention to use MA (ρ=0.48; p<0.01), increased MA tolerance (ρ=0.38; p=0.01), craving for MA (ρ=0.37; p=0.01), and MA-induced withdrawal symptoms (p<0.05). CONCLUSION: Our findings suggest that Ruminococcus-driven enterotype 2 and the genera Devosia might be two influential factors that differentiate MA casual use from MUD, but further studies are warranted.
format Online
Article
Text
id pubmed-9996337
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99963372023-03-10 Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder He, Li Yang, Bao-Zhu Ma, Yue-Jiao Wen, Li Liu, Feng Zhang, Xiao-Jie Liu, Tie-Qiao Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: The transition from methamphetamine (MA) casual use (MCU) to compulsive use is enigmatic as some MA users can remain in casual use, but some cannot. There is a knowledge gap if gut microbiota (GM) play a role in differing MCU from MA use disorder (MUD). We aimed to investigate the clinical features and GM differences between individuals with MCU and MUD. METHOD: We recruited two groups of MA users –MCU and MUD – and matched them according to age and body mass index (n=21 in each group). Participants were accessed using the Semi-Structured Assessment for Drug Dependence and Alcoholism, and their fecal samples were undergone 16S ribosomal DNA sequencing. We compared the hosts’ clinical features and GM diversity, composition, and structure (represented by enterotypes) between the two groups. We have identified differential microbes between the two groups and performed network analyses connecting GM and the clinical traits. RESULT: Compared with the casual users, individuals with MUD had higher incidences of MA-induced neuropsychiatric symptoms (e.g., paranoia, depression) and withdrawal symptoms (e.g., fatigue, drowsiness, and increased appetite), as well as stronger cravings for and intentions to use MA, and increased MA tolerance. The GM diversity showed no significant differences between the two groups, but four genera (Halomonas, Clostridium, Devosia, and Dorea) were enriched in the individuals with MUD (p<0.05). Three distinct enterotypes were identified in all MA users, and Ruminococcus-driven enterotype 2 was dominant in individuals with MUD compared to the MCU (61.90% vs. 28.60%, p=0.03). Network analysis shows that Devosia is the hub genus (hub index = 0.75), which is not only related to the counts of the MUD diagnostic criteria (ρ=0.40; p=0.01) but also to the clinical features of MA users such as reduced social activities (ρ=0.54; p<0.01). Devosia is also associated with the increased intention to use MA (ρ=0.48; p<0.01), increased MA tolerance (ρ=0.38; p=0.01), craving for MA (ρ=0.37; p=0.01), and MA-induced withdrawal symptoms (p<0.05). CONCLUSION: Our findings suggest that Ruminococcus-driven enterotype 2 and the genera Devosia might be two influential factors that differentiate MA casual use from MUD, but further studies are warranted. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9996337/ /pubmed/36909722 http://dx.doi.org/10.3389/fcimb.2023.1103919 Text en Copyright © 2023 He, Yang, Ma, Wen, Liu, Zhang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
He, Li
Yang, Bao-Zhu
Ma, Yue-Jiao
Wen, Li
Liu, Feng
Zhang, Xiao-Jie
Liu, Tie-Qiao
Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder
title Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder
title_full Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder
title_fullStr Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder
title_full_unstemmed Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder
title_short Differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder
title_sort differences in clinical features and gut microbiota between individuals with methamphetamine casual use and methamphetamine use disorder
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996337/
https://www.ncbi.nlm.nih.gov/pubmed/36909722
http://dx.doi.org/10.3389/fcimb.2023.1103919
work_keys_str_mv AT heli differencesinclinicalfeaturesandgutmicrobiotabetweenindividualswithmethamphetaminecasualuseandmethamphetamineusedisorder
AT yangbaozhu differencesinclinicalfeaturesandgutmicrobiotabetweenindividualswithmethamphetaminecasualuseandmethamphetamineusedisorder
AT mayuejiao differencesinclinicalfeaturesandgutmicrobiotabetweenindividualswithmethamphetaminecasualuseandmethamphetamineusedisorder
AT wenli differencesinclinicalfeaturesandgutmicrobiotabetweenindividualswithmethamphetaminecasualuseandmethamphetamineusedisorder
AT liufeng differencesinclinicalfeaturesandgutmicrobiotabetweenindividualswithmethamphetaminecasualuseandmethamphetamineusedisorder
AT zhangxiaojie differencesinclinicalfeaturesandgutmicrobiotabetweenindividualswithmethamphetaminecasualuseandmethamphetamineusedisorder
AT liutieqiao differencesinclinicalfeaturesandgutmicrobiotabetweenindividualswithmethamphetaminecasualuseandmethamphetamineusedisorder